CI · Cigna Group · Financials

$314.37 +8.96 (+2.93%) Earnings today Play latest call Q2 2026 earnings call transcript

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$80.70B

264.24M

Volume · Nov 5 630.68K Avg daily vol (3M) 1.61M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$274.9B +11.2%

FY2025

Net Income

$5.96B +73.5%

FY2025

Gross Margin

21.79% -4.4pp

FY2025

Operating Margin

3.35% -0.5pp

FY2025

Diluted EPS

$22.18 +83%

FY2025

Operating Cash Flow

$9.6B -7.4%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	+15.0%	+11.4%	—	$280B*	$282.38B	$274.9B	$247.12B	$195.27B	$180.52B	$174.07B^G	$160.4B^G	$153.57B	$48.65B	$41.81B	$39.84B
Premiums Earned (Net)	+0.3%	-1.1%	—	—	$38.04B	$40.26B	$46B	$44.24B	$39.92B	$41.15B	$42.63B	$39.71B	$36.11B	$32.49B	$30.82B
Cost of Revenue	+19.9%	+15.7%	—	—	$224.13B	$214.99B	$182.51B	$133.8B	$124.83B	$117.55B	$103.48B	$97.67B	$4.79B	$2.46B	$2.47B
Gross Profit	+2.5%	+1.0%	—	—	$58.25B	$59.91B	$64.61B	$61.46B	$55.68B	$56.52B	$56.92B	$55.9B	$43.86B	$39.35B	$37.37B
Gross Margin	—	—	—	—	—	21.79%	26.15%	31.48%	30.85%	32.47%	35.48%	36.4%	90.15%	94.13%	93.8%
Selling, General & Administrative	+3.5%	+0.8%	—	—	$14.16B	$14.62B	$14.84B	$14.82B	$13.17B	$13.01B	$14.07B	$14.05B	$11.93B	$10.03B	$9.79B
Amortization of Intangibles	-2.4%	-2.5%	—	—	$1.68B	$1.74B	$1.7B	$1.82B	$1.88B	$2B	$1.98B	$2.95B	$235M	$115M	$151M
Depreciation & Amortization	-1.9%	-0.2%	—	—	$2.72B	$2.78B	$2.78B	$3.04B	$2.94B	$2.92B	$2.8B	$3.65B	$695M	$566M	$610M
Restructuring Charges	—	—	—	—	—	—	$0	$252M	$22M	$168M	—	—	—	—	—
Operating Income	+2.9%	+2.4%	—	—	$9.96B	$9.2B	$9.42B	$8.54B	$8.45B	$7.94B	$8.15B	$8.08B	$4.16B	$3.94B	$3.09B
Operating Margin	—	—	—	—	—	3.35%	3.81%	4.37%	4.68%	4.56%	5.08%	5.26%	8.55%	9.43%	7.75%
EBITDA	+1.7%	+1.8%	—	—	$12.68B	$11.98B	$12.19B	$11.57B	$11.39B	$10.86B	$10.96B	$11.73B	$4.86B	$4.51B	$3.7B
Other Non-Operating Income	—	—	—	—	-$1.42B	-$1.41B	-$1.44B	-$1.45B	-$1.23B	-$1.21B	-$1.44B	-$1.68B	-$498M	-$252M	-$278M
Pretax Income	-2.5%	-6.5%	—	—	$8.64B	$7.78B	$5.27B	$5.51B	$8.4B	$6.79B	$10.87B	$6.57B	$3.58B	$3.61B	$2.98B
Income Tax	-2.6%	-8.9%	—	—	$1.66B	$1.49B	$1.49B	$141M	$1.62B	$1.37B	$2.38B	$1.45B	$935M	$1.37B	$1.14B
Net Income	-4.2%	-6.8%	—	—	$6.42B	$5.96B	$3.43B	$5.16B	$6.78B	$5.42B	$8.49B	$5.12B	$2.65B	$2.23B	$1.84B
Net Margin	—	—	—	—	—	2.17%	1.39%	2.64%	3.76%	3.11%	5.29%	3.33%	5.44%	5.34%	4.63%
Net Income Attributable to Noncontrolling Interests	+61.9%	+60.6%	—	—	$567M	$331M	$344M	$208M	$78M	$50M	$31M	$16M	$9M	-$5M	-$24M
Net Income Available to Common Stockholders	—	—	—	—	—	—	$3.43B	$5.16B	$6.7B	$5.37B	$8.46B	$5.1B	$2.64B	$2.24B	$1.87B
Comprehensive Income	-3.5%	-8.4%	—	—	$4.87B	$5.49B	$2.96B	$4.96B	$6.11B	$5.33B	$8.54B	$5.87B	$2.25B	$2.54B	$1.74B
EPS (Basic) USD/shares	+1.0%	-0.7%	—	—	$24.30	$22.33	$12.25	$17.57	$21.66	$15.89	$23.17	$13.58	$10.69	$8.92	$7.31
EPS (Diluted) USD/shares	+1.2%	-0.7%	—	at least $30.45*	$24.17	$22.18^G	$12.12	$17.39^G	$21.41^G	$15.75^G	$22.96^G	$13.44	$10.54	$8.77	$7.19
Shares Outstanding (Diluted Avg) shares	-5.0%	-6.1%	—	—	—	268.56M	283.22M	296.88M	313.07M	340.97M	368.39M	379.82M	250.23M	255.07M	259.65M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $37.52B in buybacks, $7.38B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Current debt and lease obligations	2026-06-30	USD 2,792,000,000	10-Q filed 2026-07-30
Noncurrent long-term debt and lease obligations	2026-06-30	USD 29,086,000,000	10-Q filed 2026-07-30

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

4.500% Senior Notes due 2030

Note · The Cigna Group

Reference: 4.500% Senior Notes due 2030

Active

Original principal: USD 1,000,000,000
Outstanding: —
Commitment: —
Availability: —
Maturity: Sep 15, 2030

Last reported interest terms: 4.5% Reported 2025-09-04 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history

Issuance · 8-K · 2025-09-04 — 8-K

Issuance · 2025-09-04 Original principal USD 1,000,000,000 Exact source document Parent 8-K filing · 2025-09-04
On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

Issuer evidence: On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

Supporting evidence: The 2030 Notes will bear interest at a rate of 4.500% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2030. The 2032 Notes will bear interest at a rate of 4.875% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2032. The 2036 Notes will bear interest at a rate of 5.250% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2036. The 2056 Notes will bear interest at a rate of 6.000% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2056.

Supporting evidence: On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

4.875% Senior Notes due 2032

Note · The Cigna Group

Reference: 4.875% Senior Notes due 2032

Active

Original principal: USD 1,250,000,000
Outstanding: —
Commitment: —
Availability: —
Maturity: Sep 15, 2032

Last reported interest terms: 4.875% Reported 2025-09-04 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history

Issuance · 8-K · 2025-09-04 — 8-K

Issuance · 2025-09-04 Original principal USD 1,250,000,000 Exact source document Parent 8-K filing · 2025-09-04
On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

Issuer evidence: On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

Supporting evidence: The 2030 Notes will bear interest at a rate of 4.500% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2030. The 2032 Notes will bear interest at a rate of 4.875% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2032. The 2036 Notes will bear interest at a rate of 5.250% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2036. The 2056 Notes will bear interest at a rate of 6.000% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2056.

Supporting evidence: On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

5.250% Senior Notes due 2036

Note · The Cigna Group

Reference: 5.250% Senior Notes due 2036

Active

Original principal: USD 1,500,000,000
Outstanding: —
Commitment: —
Availability: —
Maturity: Jan 15, 2036

Last reported interest terms: 5.25% Reported 2025-09-04 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history

Issuance · 8-K · 2025-09-04 — 8-K

Issuance · 2025-09-04 Original principal USD 1,500,000,000 Exact source document Parent 8-K filing · 2025-09-04
On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

Issuer evidence: On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

Supporting evidence: The 2030 Notes will bear interest at a rate of 4.500% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2030. The 2032 Notes will bear interest at a rate of 4.875% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2032. The 2036 Notes will bear interest at a rate of 5.250% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2036. The 2056 Notes will bear interest at a rate of 6.000% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2056.

Supporting evidence: On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

0.37×

Peer median 0.37×

EV/EBIT

10.58×

Peer median 17.25×

P/E (TTM)

12.64×

Peer median 23.37×

Price/Sales (TTM)

0.29×

Peer median 0.34×

Price/Book

1.89×

Peer median 2.61×

Peer medians compare against the 7 similar-size Healthcare Plans companies (of 13 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Evernorth	$234,953,000,000	$201,973,000,000	$153,499,000,000	$140,335,000,000	$131,912,000,000	$116,334,000,000	$109,794,000,000	$7,065,000,000
Cigna Healthcare	$47,412,000,000	$53,118,000,000	$51,148,000,000	$44,911,000,000	$44,643,000,000	$41,265,000,000	$39,133,000,000	—
All Other Segments	$674,000,000	$828,000,000	$596,000,000	$2,263,000,000	$3,989,000,000	$8,446,000,000	$8,215,000,000	—
Group Disability and Other	—	—	—	—	—	$5,264,000,000	$5,182,000,000	$5,061,000,000
International Markets	—	—	—	—	—	$6,007,000,000	$5,659,000,000	$5,323,000,000
US Medical	—	—	—	—	—	$38,451,000,000	$36,519,000,000	$32,791,000,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Product	$216,672,000,000	$185,362,000,000	$137,243,000,000	$128,566,000,000	$121,413,000,000	$107,769,000,000	$103,099,000,000	$5,479,000,000
Service Fees and Other Revenues	$16,921,000,000	$14,790,000,000	$12,619,000,000	$10,881,000,000	—	—	—	—
Service	$16,921,000,000	$14,790,000,000	$12,619,000,000	$10,881,000,000	$9,953,000,000	$8,761,000,000	$9,363,000,000	$5,578,000,000
Service Other	$696,000,000	$584,000,000	$210,000,000	$168,000,000	$188,000,000	$254,000,000	$157,000,000	$20,000,000
Home Delivery and Specialty	—	—	$65,732,000,000	$61,283,000,000	$54,391,000,000	$49,906,000,000	$49,226,000,000	$3,997,000,000
Network Pharmacy	—	—	$67,514,000,000	$64,946,000,000	$64,992,000,000	$56,365,000,000	$51,430,000,000	$1,415,000,000
Other Pharmacy	—	—	$9,047,000,000	$6,753,000,000	$6,428,000,000	$5,403,000,000	$4,900,000,000	$67,000,000
Service Fees	—	—	—	—	—	$8,532,000,000	$9,229,000,000	$5,558,000,000

Key facts CIK 1739940 CUSIP 125523100 13F (30d) 815 filings 763 filers Visit website Investor relations